<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39557332</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1638-6183</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>16</Day></PubDate></JournalIssue><Title>Biochimie</Title><ISOAbbreviation>Biochimie</ISOAbbreviation></Journal><ArticleTitle>Does hypersialylation compensate the functional Alpha1-AntiTrypsin (A1AT) deficiency in all critically ill patients?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0300-9084(24)00263-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biochi.2024.11.008</ELocationID><Abstract><AbstractText>Alpha-1 antitrypsin (A1AT) is the major circulating serine protease inhibitor. Hypersialylated glycoforms (HSG) are produced to boost A1AT anti-inflammatory and anti-protease properties. Their occurrence and prognostic impact outside severe COVID-19 or community-acquired pneumonia are unknown. Our aim was to clarify the occurrence of A1AT functional deficiency and HSG in patients admitted into intensive care unit (ICU) for any cause. A1AT and elastase inhibitory capacity (EIC) were measured in serum. Functional A1AT deficiency was defined by a measured EIC/calculated EIC Ratio ≤0.85. HSG were identified by isoelectrofocusing and quantified by gel densitometry. A total of 248 serum samples was analyzed , 173 from COVID-19 and 75 from non COVID-19 patients. A functional A1AT deficiency occurred 3-fold more frequently in non-COVID-19 than in COVID-19 patients: 18.7% vs 6.9% and was not associated with more frequent S/Z deficient alleles. Functional deficiency was also more frequent in deceased than alive patients in COVID-19 group. M0 and M1 HSG of A1AT occurred in around half of patients but the relative proportion of M1 significantly increased in deceased vs alive patients only in the non-COVID-19 group explaining the absence of worsening of the functional deficiency. In conclusion, our study shows that a functional A1AT deficiency is more frequently observed in patients admitted to the ICU for a cause unrelated to COVID-19, as well as in those with an unfavorable evolution. Among the latter, only those admitted for non-COVID-19 tried to compensate the functional deficiency by increasing the proportion of M1 HSG of A1AT.</AbstractText><CopyrightInformation>Copyright © 2024. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Balduyck</LastName><ForeName>Malika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie « Hormonologie, Métabolisme, Nutrition &amp; Oncologie », CHU, F-59037 Lille cedex France; Univ. Lille ULR 7364-RADEME, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afif</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie « Hormonologie, Métabolisme, Nutrition &amp; Oncologie », CHU, F-59037 Lille cedex France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onraed</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie automatisée, Protéines, CHU, F-59037 Lille cedex France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jourdain</LastName><ForeName>Mercédes</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service de Médecine Intensive-Réanimation, CHU, F-59000 Lille cedex; Université de Lille, INSERM U1190, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nseir</LastName><ForeName>Saad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service de Médecine Intensive-Réanimation, CHU, F-59000 Lille cedex; Inserm U1285, Université de Lille, CNRS, UMR 8576 - UGSF, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pigny</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie « Hormonologie, Métabolisme, Nutrition &amp; Oncologie », CHU, F-59037 Lille cedex France; Inserm U1277, Université de Lille, CANTHER, place de Verdun, F-59045 Lille cedex France. Electronic address: pascal.pigny@chu-lille.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zerimech</LastName><ForeName>Farid</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie « Hormonologie, Métabolisme, Nutrition &amp; Oncologie », CHU, F-59037 Lille cedex France; Univ. Lille ULR 4483 - IMPECS, Institut Pasteur Lille, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>LICORNE study group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Biochimie</MedlineTA><NlmUniqueID>1264604</NlmUniqueID><ISSNLinking>0300-9084</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">(max 6): alpha-1 antitrypsin</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">elastase</Keyword><Keyword MajorTopicYN="N">glycoforms</Keyword><Keyword MajorTopicYN="N">hypersialylation</Keyword><Keyword MajorTopicYN="N">intensive care unit</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest ☒ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: PASCAL PIGNY reports financial support was provided by LFB BIOMEDICAMENTS. PASCAL PIGNY reports a relationship with LFB BIOMEDICAMENTS that includes: funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Deplanque</LastName><ForeName>Dominique</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faure</LastName><ForeName>Karine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lefevre</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alidjinou</LastName><ForeName>Kazali</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bordet</LastName><ForeName>Régis</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Engelmann</LastName><ForeName>Ilka</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garrigue</LastName><ForeName>Delphine</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goffard</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kipnis</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Labalette</LastName><ForeName>Myriam</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lambert</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Launay</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathieu</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maurage</LastName><ForeName>Claude Alain</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poissy</LastName><ForeName>Julien</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Remy</LastName><ForeName>Martine</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sendid</LastName><ForeName>Boualem</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Susen</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caillier</LastName><ForeName>Maxime</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laurent</LastName><ForeName>Laurent Schwarb</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hisbergues</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39557332</ArticleId><ArticleId IdType="doi">10.1016/j.biochi.2024.11.008</ArticleId><ArticleId IdType="pii">S0300-9084(24)00263-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle>